Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 20 de 356 siguiente >>
Presentar resultados
Seleccionar todas
2.Enlace a cita original Cita con resumen
Anónimo. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. U.S. Food and Drug Administration 2019:21 de junio. [Ref.ID 103134]
3.Enlace a cita original Cita con resumen
Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]
4.Enlace a cita original Cita con resumen
Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]
5. Cita con resumen
Anónimo. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). U.S. Food and Drug Administration 2019:21 de febrero. [Ref.ID 103045]
6.Enlace a cita original Cita con resumen
Christensen J, Pedersen LH, Sun Y, Dreier JW, Brikell I, Dalsqaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Network Open 2019;2:4 de enero. [Ref.ID 103010]
7.Enlace a cita original Cita con resumen
Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102884]
8.Enlace a cita original Cita con resumen
Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ 2018;363:14 de noviembre. [Ref.ID 102868]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ 2018;361:18 de abril. [Ref.ID 102682]
10.Enlace a cita original Cita con resumen
Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]
12.Enlace a cita original Cita con resumen
13. Cita con resumen
Hirschler B. UK bans Sanofi epilepsy drug without pregnancy prevention plan. Reuters Health News 2018:24 de abril. [Ref.ID 102553]
14. Cita con resumen
Anónimo. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone. European Medical Agency 2018:1. [Ref.ID 102552]
17. Cita con resumen
Herzig SJ, Mosher HJ, Calcaterra SL, Jena AB, Nuckols TK. Improving the safety of opioid use for acute noncancer pain in hospitalized adults: a consensus statement from the Society of Hospital Medicine. J Hosp Med 2018;13:abril. [Ref.ID 102501]
18. Cita con resumen
Varga S, Alcusky M, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017;83:2572-80. [Ref.ID 102117]
19.Enlace a cita original Cita con resumen
Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett-Connor E, Temprosa M, on behalf of the Diabetes Prevention Program(DPP) Research Group. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.. BMJ Open Diabetes Research & Care 2017;5:1-10. [Ref.ID 102101]
20. Cita con resumen
Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzlez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf 2017;26:615-24. [Ref.ID 101961]
Seleccionar todas
 
 1 a 20 de 356 siguiente >>